245 related articles for article (PubMed ID: 25403517)
1. Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid.
Jelaković B; Castells X; Tomić K; Ardin M; Karanović S; Zavadil J
Int J Cancer; 2015 Jun; 136(12):2967-72. PubMed ID: 25403517
[TBL] [Abstract][Full Text] [Related]
2. Aristolochic Acid in the Etiology of Renal Cell Carcinoma.
Hoang ML; Chen CH; Chen PC; Roberts NJ; Dickman KG; Yun BH; Turesky RJ; Pu YS; Vogelstein B; Papadopoulos N; Grollman AP; Kinzler KW; Rosenquist TA
Cancer Epidemiol Biomarkers Prev; 2016 Dec; 25(12):1600-1608. PubMed ID: 27555084
[TBL] [Abstract][Full Text] [Related]
3. Balkan Endemic Nephropathy and the Causative Role of Aristolochic Acid.
Jelaković B; Dika Ž; Arlt VM; Stiborova M; Pavlović NM; Nikolić J; Colet JM; Vanherweghem JL; Nortier JL
Semin Nephrol; 2019 May; 39(3):284-296. PubMed ID: 31054628
[TBL] [Abstract][Full Text] [Related]
4. Low-Coverage Exome Sequencing Screen in Formalin-Fixed Paraffin-Embedded Tumors Reveals Evidence of Exposure to Carcinogenic Aristolochic Acid.
Castells X; Karanović S; Ardin M; Tomić K; Xylinas E; Durand G; Villar S; Forey N; Le Calvez-Kelm F; Voegele C; Karlović K; Mišić M; Dittrich D; Dolgalev I; McKay J; Shariat SF; Sidorenko VS; Fernandes A; Heguy A; Dickman KG; Olivier M; Grollman AP; Jelaković B; Zavadil J
Cancer Epidemiol Biomarkers Prev; 2015 Dec; 24(12):1873-81. PubMed ID: 26383547
[TBL] [Abstract][Full Text] [Related]
5. Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy.
Schmeiser HH; Nortier JL; Singh R; Gamboa da Costa G; Sennesael J; Cassuto-Viguier E; Ambrosetti D; Rorive S; Pozdzik A; Phillips DH; Stiborova M; Arlt VM
Int J Cancer; 2014 Jul; 135(2):502-7. PubMed ID: 24921086
[TBL] [Abstract][Full Text] [Related]
6. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid.
Hollstein M; Moriya M; Grollman AP; Olivier M
Mutat Res; 2013; 753(1):41-49. PubMed ID: 23422071
[TBL] [Abstract][Full Text] [Related]
7. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease.
Grollman AP
Environ Mol Mutagen; 2013 Jan; 54(1):1-7. PubMed ID: 23238808
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool.
Poon SL; Pang ST; McPherson JR; Yu W; Huang KK; Guan P; Weng WH; Siew EY; Liu Y; Heng HL; Chong SC; Gan A; Tay ST; Lim WK; Cutcutache I; Huang D; Ler LD; Nairismägi ML; Lee MH; Chang YH; Yu KJ; Chan-On W; Li BK; Yuan YF; Qian CN; Ng KF; Wu CF; Hsu CL; Bunte RM; Stratton MR; Futreal PA; Sung WK; Chuang CK; Ong CK; Rozen SG; Tan P; Teh BT
Sci Transl Med; 2013 Aug; 5(197):197ra101. PubMed ID: 23926199
[TBL] [Abstract][Full Text] [Related]
9. Aristolochic acid nephropathy: a worldwide problem.
Debelle FD; Vanherweghem JL; Nortier JL
Kidney Int; 2008 Jul; 74(2):158-69. PubMed ID: 18418355
[TBL] [Abstract][Full Text] [Related]
10. Aristolochic acid-associated urothelial cancer in Taiwan.
Chen CH; Dickman KG; Moriya M; Zavadil J; Sidorenko VS; Edwards KL; Gnatenko DV; Wu L; Turesky RJ; Wu XR; Pu YS; Grollman AP
Proc Natl Acad Sci U S A; 2012 May; 109(21):8241-6. PubMed ID: 22493262
[TBL] [Abstract][Full Text] [Related]
11. Mutational signature of aristolochic acid: Clue to the recognition of a global disease.
Rosenquist TA; Grollman AP
DNA Repair (Amst); 2016 Aug; 44():205-211. PubMed ID: 27237586
[TBL] [Abstract][Full Text] [Related]
12. TP53 Mutational signature for aristolochic acid: an environmental carcinogen.
Moriya M; Slade N; Brdar B; Medverec Z; Tomic K; Jelaković B; Wu L; Truong S; Fernandes A; Grollman AP
Int J Cancer; 2011 Sep; 129(6):1532-6. PubMed ID: 21413016
[TBL] [Abstract][Full Text] [Related]
13. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.
Lu H; Liang Y; Guan B; Shi Y; Gong Y; Li J; Kong W; Liu J; Fang D; Liu L; He Q; Shakeel M; Li X; Zhou L; Ci W
Theranostics; 2020; 10(10):4323-4333. PubMed ID: 32292497
[No Abstract] [Full Text] [Related]
14. Aristolochic acid and the etiology of endemic (Balkan) nephropathy.
Grollman AP; Shibutani S; Moriya M; Miller F; Wu L; Moll U; Suzuki N; Fernandes A; Rosenquist T; Medverec Z; Jakovina K; Brdar B; Slade N; Turesky RJ; Goodenough AK; Rieger R; Vukelić M; Jelaković B
Proc Natl Acad Sci U S A; 2007 Jul; 104(29):12129-34. PubMed ID: 17620607
[TBL] [Abstract][Full Text] [Related]
15. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid.
Jelaković B; Karanović S; Vuković-Lela I; Miller F; Edwards KL; Nikolić J; Tomić K; Slade N; Brdar B; Turesky RJ; Stipančić Ž; Dittrich D; Grollman AP; Dickman KG
Kidney Int; 2012 Mar; 81(6):559-67. PubMed ID: 22071594
[TBL] [Abstract][Full Text] [Related]
16. Aristolochic acid exposure in Romania and implications for renal cell carcinoma.
Turesky RJ; Yun BH; Brennan P; Mates D; Jinga V; Harnden P; Banks RE; Blanche H; Bihoreau MT; Chopard P; Letourneau L; Lathrop GM; Scelo G
Br J Cancer; 2016 Jan; 114(1):76-80. PubMed ID: 26657656
[TBL] [Abstract][Full Text] [Related]
17. p53 mutations as fingerprints for aristolochic acid: an environmental carcinogen in endemic (Balkan) nephropathy.
Slade N; Moll UM; Brdar B; Zorić A; Jelaković B
Mutat Res; 2009 Apr; 663(1-2):1-6. PubMed ID: 19428366
[TBL] [Abstract][Full Text] [Related]
18. Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer.
Arlt VM; Stiborová M; vom Brocke J; Simões ML; Lord GM; Nortier JL; Hollstein M; Phillips DH; Schmeiser HH
Carcinogenesis; 2007 Nov; 28(11):2253-61. PubMed ID: 17434925
[TBL] [Abstract][Full Text] [Related]
19. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review.
Arlt VM; Stiborova M; Schmeiser HH
Mutagenesis; 2002 Jul; 17(4):265-77. PubMed ID: 12110620
[TBL] [Abstract][Full Text] [Related]
20. Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of Romania.
Schmeiser HH; Kucab JE; Arlt VM; Phillips DH; Hollstein M; Gluhovschi G; Gluhovschi C; Modilca M; Daminescu L; Petrica L; Velciov S
Environ Mol Mutagen; 2012 Oct; 53(8):636-41. PubMed ID: 22987305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
